Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$75.66M

FY 2025 · Annual

+140.4% YoY

Investing Cash Flow

-$92.36M

FY 2025 · Annual

Financing Cash Flow

$601,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
Deferred Income Tax0000(245.85M)
Stock-Based Compensation9.49M12.39M8.81M12.39M12.71M
Change in Working Capital9.72M(29.05M)9.52M153K(19.51M)
Accounts Receivables501K(24.85M)9.77M(11.07M)(10.15M)
Inventory(4.88M)(2.38M)1.17M764K(5.64M)
Accounts Payables41K3.79M(366K)(3.8M)3.85M
Other Working Capital14.05M(5.61M)(1.06M)14.26M(7.58M)
Other Non-Cash Items3.43M481K(213K)(788K)(41.13M)
Operating Cash Flow5.88M(73.76M)(5.74M)31.47M75.66M
Capital Expenditures(627K)(450K)(15M)(396K)0
Acquisitions (Net)00000
Purchases of Investments(141.46M)(28.89M)(31.21M)(35.27M)(153.49M)
Sales of Investments62.05M101.23M41.65M39.7M61.13M
Other Investing Activities0893K259K98K0
Investing Cash Flow(80.04M)72.78M(4.3M)4.13M(92.37M)
Debt Repayment019.54M19.95M0(7.5M)
Common Stock Issued00008.1M
Common Stock Repurchased000(10M)0
Dividends Paid00000
Other Financing Activities62.68M(12.99M)(1.58M)(1.64M)0
Financing Cash Flow62.68M6.55M18.37M(11.64M)601K
Effect of Forex Changes00000
Net Change in Cash(11.48M)5.57M8.33M23.96M(16.11M)
Free Cash Flow5.25M(74.21M)(20.74M)31.08M75.66M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$367.0M
+ D&A$2.4M
+ Stock-Based Comp$12.7M
- Deferred Tax-$245.9M
- Working Capital-$19.5M
- Other Non-Cash-$41.1M
= Operating Cash Flow$75.7M
- Capex$0
= Free Cash Flow$75.7M

Analysis

FY2025 free cash flow is $75.7M. FCF conversion is 20.6% of net income. Operating cash flow was $75.7M, with capex of $0. The largest bridge item is Deferred Tax at -$245.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipSep 3, 2026

Does RIGL generate free cash flow?

Rigel Pharmaceuticals, Inc. (RIGL) generated $75.66M of free cash flow in fiscal 2025.

How much operating cash flow does RIGL produce?

Operating cash flow was $75.66M, before capital expenditures of $0.00.